Advertisements


Agenus: Out Of Favor Immuno-Oncology Pioneer Powers On

Agenus: Out Of Favor Immuno-Oncology Pioneer Powers On.....»»

Category: topSource: seekingalphaJul 11th, 2019

Agenus stock shoots up 60% after announcing drug development deal with Gilead

Shares of Agenus Inc. shot up 60% in premarket trade Thursday after the company announced it was partnering with Gilead Sciences Inc. to develop up to five immuno-oncology therapies. Under the deal, Agenus will receive $150 millio.....»»

Category: topSource: marketwatchDec 20th, 2018

Gilead, Agenus enter into immuno-oncology partnership

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 20th, 2018

Gilead, Agenus enter into immuno-oncology partnership

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 20th, 2018

Nektar presents new clinical, preclinical data from immuno-oncology pipeline

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 10th, 2019

Qiagen expands portfolio of immuno-oncology assets

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 5th, 2019

Medicenna Reports Second Quarter Fiscal 2020 Financial Results

TORONTO and HOUSTON, Nov. 5, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTCQB:MDNAF), a clinical stage immuno-oncology company, today reported financial results for the three and si.....»»

Category: earningsSource: benzingaNov 5th, 2019

Generex announces merger for public trading of NuGenerex Immuno-Oncology

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 15th, 2019

Here are the first four investments from Venture Investors" new $75M health VC fund

Invenra Inc., a Madison startup that developed a drug discovery platform to identify human multi-specific antibodies for immuno-oncology, is one of the four startups to receive an investment from Wisconsin's Venture Investors. The funding comes fr.....»»

Category: topSource: bizjournalsOct 6th, 2019

Immuno-Oncology Firm Innate Pharma Files For U.S. IPO

Immuno-Oncology Firm Innate Pharma Files For U.S. IPO.....»»

Category: topSource: seekingalphaSep 26th, 2019

IGM Biosciences hits middle of boosted targets with $175M IPO

IGM Biosciences Inc. raised $175 million on Wednesday after it hit the middle of its IPO target range a day after boosting the number of shares it sold. The Mountain View preclinical immuno-oncology biotech sold 10.9 million shares at $16 each. The.....»»

Category: topSource: bizjournalsSep 18th, 2019

Philadelphia Immuno-oncology company Imvax hires CEO

The company's first full-time CEO was formerly the COO at Spark Therapeutics......»»

Category: topSource: bizjournalsSep 10th, 2019

Idera Pharmaceuticals, AbbVie enter immuno-oncology research collaboration

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 4th, 2019

Cancer Genetics Reports Second Quarter 2019 Financial Results and Provides Strategic Business Update

RUTHERFORD, N.J., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (NASDAQ:CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, .....»»

Category: earningsSource: benzingaAug 20th, 2019

Merus Announces Financial Results for the Second Quarter 2019 and Provides Business Update

UTRECHT, The Netherlands, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "we", "our" or the "Company"), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length hu.....»»

Category: earningsSource: benzingaAug 19th, 2019

Roche"s Tecentriq Gets CHMP Recommendation for Breast Cancer

Roche (RHHBY) announced that its immuno-oncology drug, Tecentriq, was recommended for approval by.....»»

Category: worldSource: nytJul 1st, 2019

Gilead Inks Deal With Carna Biosciences for Immuno-Oncology

Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small mol.....»»

Category: worldSource: nytJun 26th, 2019

The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership

The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership.....»»

Category: earningsSource: benzingaJun 25th, 2019

Hemispherx CEO says company has "steady, consistent" progress in immuno-oncology

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 17th, 2019

Price target on Bristol-Myers stock cut to $51 at UBS

Analysts at UBS cut their price target on shares of Bristol-Myers Squibb Co. on Thursday to $51 from $55 per share, citing lower-than-consensus expectations for the company's immuno-oncology franchise. The firm holds "cautious vi.....»»

Category: topSource: marketwatchJun 13th, 2019

Genocea surges after selection as top 10 featured ASCO immuno-oncology abstract

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 31st, 2019